Key result
Sacubitril/valsartan associated with rapid clinical improvement and reduced hospitalizations in HFrEF case reports.
Why the study?
Does sacubitril/valsartan improve clinical outcomes and reduce hospitalizations in patients with HFrEF?
Population
Three male patients with HFrEF (one 49 years old, two 70 years old)
Comparison
Sacubitril/valsartan after previous ineffective treatment
Design
Case series
Authors
Loading...
Should not yet change HFrEF practice; hypothesis-generating in three cases and requires randomized confirmation.
Case Report (n=3)
Does sacubitril/valsartan improve clinical outcomes and reduce hospitalizations in patients with HFrEF?
Sacubitril/valsartan may provide significant clinical improvement and reduce hospitalizations or the need for ICDs in patients with HFrEF refractory to previous treatments.
Severini et al. (2019) conducted a case report in Heart failure with reduced left ventricular ejection fraction (HFrEF) (n=3). Sacubitril/valsartan vs. Previous ineffective treatment was evaluated on Clinical conditions and hospitalization rate. Sacubitril/valsartan administration led to a rapid and marked improvement of clinical conditions and reduced hospitalizations in three male patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: